IL17A and idiopathic pulmonary fibrosis: Loss of IL-17 ameliorated airway inflammation and PF in this model by reducing the number of pulmonary neutrophils and eosinophils, and enhancing Treg cell response in the lungs, which suggests that IL-17 is a potential therapeutic target for AE-IPF induced by NTHi.